Last updated on October 2017

Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema


Brief description of study

This 3-part study will evaluate the efficacy and safety of an oral kallikrein inhibitor, BCX7353, in the treatment angioedema attacks in subjects with Type I or II hereditary angioedema (HAE). In each study part, subjects will treat 3 attacks with BCX7353 (2 attacks) or placebo (1 attack), in a randomly allocated order. In Part 1, the dose of 750mg will be assessed relative to placebo in up to 36 patients. If this is shown to be effective, then a further 12 patients will be enrolled at a 500mg dose (Part 1), followed by a further 12 (if efficacy still shown) at a dose of 250mg (Part 3) to determine the minimum effective dose of BCX7353 compared to placebo for treating HAE attacks. Efficacy will be determined by subject diary entries completed at pre-defined times post-dose.

Clinical Study Identifier: NCT03240133

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Clinical Trials

Study Center
Graz, Austria
  Connect »

Clinical Trials

Study Center
Grenoble, France
  Connect »

Clinical Trials

Study Center
Berlin, Germany
  Connect »

Clinical Trials

Study Center
Budapest, Hungary
  Connect »